Multiple centre evaluation study of <scp>ADAMTS</scp>13 activity and inhibitor assays
K. Langley(University College London), Marie Scully(University College London Hospitals NHS Foundation Trust), Tina Dutt(University of Liverpool), R. Fretwell(Royal Hallamshire Hospital), Cían Hughes(St James's University Hospital), Vickie McDonald(University College London), Paul Murphy(Newcastle upon Tyne Hospitals NHS Foundation Trust), Stephen MacDonald(Cambridge University Hospitals NHS Foundation Trust), Deepak Singh(Doctors of the World), Peter Baker(Oxford University Hospitals NHS Trust), Steve Kitchen(Royal Hallamshire Hospital)
Cited by 11
Related Papers
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
|British Journal of Haematology|2012|861
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura
|Blood|2011|420
Regional UK TTP Registry: correlation with laboratory ADAMTS 13 analysis and clinical features
|British Journal of Haematology|2008|376
Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS‐13
|British Journal of Haematology|2006|267
Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse
|Journal of Thrombosis and Haemostasis|2012|175